Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 6/20 | 0.44 |
| ▸ | HRH1 | P35367 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | AQP1 | P29972 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485140 | 1.00 | HRH3 (0.49) | HRH3GPBAR1HTR2AHRH1HTR2C | |
| SCHEMBL8036558 | 0.83 | HRH3 (0.47) | HRH3GPBAR1HTR2AHRH1HTR1A | |
| SCHEMBL6921396 | 0.83 | CA2 (0.62) | HTR1AHTR1DCA2DRD2ADRA2A | |
| SCHEMBL13181762 | 0.82 | HRH3 (0.46) | HRH3GPBAR1HTR2AHTR1AHTR1D | |
| SCHEMBL11884680 | 0.82 | CA2 (0.47) | HRH3GPBAR1HTR2AHTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL6924157 | 0.81 | CA2 (0.61) | HTR1AHTR1DCA2DRD2ADRA2A | |
| SCHEMBL8035957 | 0.80 | DRD2 (0.53) | HTR2ADRD2DRD4DRD3 | |
| SCHEMBL434338 | 0.79 | HRH3 (0.49) | HRH3GPBAR1HTR2ACA2DRD2 | |
| SCHEMBL434889 | 0.79 | CA2 (0.44) | HRH3GPBAR1HTR1AHTR1DCA2 | |
| SCHEMBL17753764 | 0.79 | MTNR1A (0.65) | GPBAR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402799-B1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-108699077-B | Heterocyclic compounds as RSV inhibitors | 英安塔制药有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2019-02-07 | — | — | US | disclosed |
| EP-3402799-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017123884-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| EP-2483277-B1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-9175009-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150094347-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-04-02 | — | — | US | disclosed |
| US-8673952-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2013-01-10 | — | — | US | disclosed |
| US-8263633-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R2 | HRH3 3002/4885GPBAR1 957/4885HTR2A 3956/4885 |
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | HRH3 503/4885GPBAR1 1374/4885HTR2A 3772/4885 |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | HRH3 503/4885GPBAR1 1374/4885HTR2A 3772/4885 |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | HRH3 1234/4885GPBAR1 1771/4885HTR2A 4062/4885 |
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | HRH3 1068/4885GPBAR1 1175/4885HTR2A 1246/4885 |
| US-20150094347-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | HRH3 1234/4885GPBAR1 1771/4885HTR2A 4062/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | HRH3 1068/4885GPBAR1 1175/4885HTR2A 1246/4885 |
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | HRH3 503/4885GPBAR1 1374/4885HTR2A 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.